Informations générales (source: ClinicalTrials.gov)
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA (ALCYTA)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
août 2022
mai 2027
29 juin 2024
The study will evaluate the detection of tumor-antigen specific immune cells in cancer
patients in whom the role of the immune system is suspected.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/09/2024 13:49:42 | Contacter | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 04/09/2024 13:49:28 | Contacter | |||
Critères
Tous
Inclusion Criteria:
1. Patient aged 18 or over,
2. Patient presenting an invasive tumor pathology (proven or suspected). The location
and / or stage of which are defined for each cohort through an amendment to the
protocol,
3. Patient treated with immune-modulators or other treatments likely to modify
immunological parameters,
4. Suspicion of immune mediated response or toxicities (assessed by the immunologists),
5. Peripheral venous capital usable and compatible with the realization of 2 venous
accesses for lymphapheresis and absence of cardiovascular problem (heart failure,
arrhythmia ...), per investigator assessement,
6. Total circulating lymphocytes> 1000 / mm3,
7. Availability of DNA and RNA from the tumor,
8. Information to the patient and signature of informed consent or his legal
representative,
9. Affiliated with a social security scheme or such a scheme.
1. Patient aged 18 or over,
2. Patient presenting an invasive tumor pathology (proven or suspected). The location
and / or stage of which are defined for each cohort through an amendment to the
protocol,
3. Patient treated with immune-modulators or other treatments likely to modify
immunological parameters,
4. Suspicion of immune mediated response or toxicities (assessed by the immunologists),
5. Peripheral venous capital usable and compatible with the realization of 2 venous
accesses for lymphapheresis and absence of cardiovascular problem (heart failure,
arrhythmia ...), per investigator assessement,
6. Total circulating lymphocytes> 1000 / mm3,
7. Availability of DNA and RNA from the tumor,
8. Information to the patient and signature of informed consent or his legal
representative,
9. Affiliated with a social security scheme or such a scheme.
1. Inability to undergo study follow-up for geographical, social or psychological
reasons,
2. Infection with HIV or hepatitis B or C viruses,
3. Patients on high dose corticosteroid treatment (> 1 mg / kg continuously),
4. Any concomitant serious illness that may interfere with participation in the study
or significantly affect the results of the study (pulmonary, heart or liver
disease),
5. Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular
problems, venous access, hypocalcemia, psychological inability to undergo
extracorporeal circulation, cachexia, etc.),
6. Pregnant patient or of childbearing age without effective contraception,
7. Persons deprived of their liberty, under guardianship or legal protection.